CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

[1]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[2]  D. Green,et al.  Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3 , 2008, Cell.

[3]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[4]  Weidong Wang.  Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins , 2007, Nature Reviews Genetics.

[5]  Akiko Shimamura,et al.  Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. , 2007, The Journal of clinical investigation.

[6]  G. Schwartz,et al.  Targeting Checkpoint Kinase 1 in Cancer Therapeutics , 2007, Clinical Cancer Research.

[7]  A. D’Andrea,et al.  Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway , 2007, Molecular and Cellular Biology.

[8]  A. D’Andrea,et al.  The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents , 2007, Journal of Molecular Medicine.

[9]  Hidetaka Kobayashi,et al.  Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint , 2007, Molecular Cancer Therapeutics.

[10]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[11]  A. D’Andrea,et al.  DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. D’Andrea,et al.  Molecular pathogenesis of Fanconi anemia: recent progress. , 2006, Blood.

[13]  Z. Estrov,et al.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. , 2006, Blood.

[14]  G. Pond,et al.  Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. D’Andrea,et al.  The Fanconi Anemia/BRCA pathway: new faces in the crowd. , 2005, Genes & development.

[16]  J. Doroshow,et al.  The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial , 2005, Clinical Cancer Research.

[17]  J. Bartek,et al.  Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage , 2005, Molecular and Cellular Biology.

[18]  Jeffrey P. MacKeigan,et al.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.

[19]  M. Gonen,et al.  Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[21]  A. D’Andrea,et al.  ATR couples FANCD2 monoubiquitination to the DNA-damage response. , 2004, Genes & development.

[22]  Katia Basso,et al.  Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. , 2004, Cancer research.

[23]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[24]  Mei Liu,et al.  Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival , 2004, Oncogene.

[25]  A. Look,et al.  Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. , 2003, Developmental cell.

[26]  C. Mathew,et al.  Bi‐allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia , 2003, British journal of haematology.

[27]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[28]  Jiri Bartek,et al.  Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.

[29]  Stephen J. Elledge,et al.  MDC1 is a mediator of the mammalian DNA damage checkpoint , 2003, Nature.

[30]  A. D’Andrea,et al.  S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. , 2002, Blood.

[31]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[32]  A. D’Andrea,et al.  Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. , 2001, Experimental hematology.

[33]  B. Seed,et al.  Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. , 2001, Blood.

[34]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[35]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[36]  A. D’Andrea,et al.  The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex. , 2000, Blood.

[37]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[38]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[39]  D. Näf,et al.  Functional Activity of the Fanconi Anemia Protein FAA Requires FAC Binding and Nuclear Localization , 1998, Molecular and Cellular Biology.

[40]  E. Guinan,et al.  Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer , 1998, Molecular medicine.

[41]  D. Näf,et al.  The Fanconi anaemia proteins, FAA and FAC interact to form a nuclear complex , 1997, Nature Genetics.

[42]  A. D’Andrea,et al.  The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. , 1996, Blood.

[43]  E. Sausville,et al.  Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. , 1994, Molecular pharmacology.

[44]  A. Eastman,et al.  The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. , 2003, Cancer research.

[45]  S. Latt,et al.  Cytogenetic and flow cytometric studies of cells from patients with Fanconi's anemia. , 1982, Cytogenetics and cell genetics.